Sernova Biotherapeutics Secures FDA Orphan Drug Designation for Autologous Islet Transplantation to Prevent Post-Pancreatectomy Diabetes
核心洞察
Sernova Biotherapeutics (搜索) received FDA orphan drug designation for autologous islet transplantation using its Cell Pouch to prevent diabetes following total pancreatectomy.
The designation applies to preventing type 3c diabetes (搜索), a condition affecting patients who undergo total pancreas removal due to chronic pancreatitis (搜索) or other pancreatic diseases.
The Cell Pouch technology aims to preserve a patient's own insulin-producing islet cells without requiring immunosuppressive therapy.
Sernova Biotherapeutics (搜索) Inc. announced on June 17, 2026, that the U.S. Food and Drug Administration has granted orphan drug designation for its autologous islet transplantation approach using the proprietary Cell Pouch Bio-hybrid Organ (搜索) for the prevention of diabetes resulting from total pancreatectomy. The designation marks a significant regulatory milestone for the Toronto- and Boston-based regenerative medicine company as it expands its pipeline beyond its core type 1 diabetes (搜索) program.
The Cell Pouch is designed to support the engraftment and long-term function of transplanted therapeutic cells. In the planned clinical application, patients undergoing total pancreatectomy — typically due to debilitating pain from chronic pancreatitis (搜索) — would have their own insulin-producing islet cells isolated from the removed pancreas, placed into Sernova's Cell Pouch, and transplanted back into the body. This autologous approach negates the need for chronic immune suppression, a key differentiator from allogeneic cell transplantation strategies.
"Patients who require total pancreatectomy face a life-changing outcome: the immediate loss of pancreatic endocrine function and the risk of complex, insulin-dependent diabetes," said Melena Bellin, MD, Co-Director of the Total Pancreatectomy and Islet Autotransplant Program at the University of Minnesota and a member of Sernova's Clinical Advisory Board. "Autologous islet transplantation in Sernova's Cell Pouch has the potential to preserve a patient's own insulin-producing cells following pancreatic surgery, without the use of immune suppressing therapies."
Orphan Drug Designation Benefits
Orphan drug designation is granted by the FDA to support the development of drugs and biologics intended to treat, diagnose, or prevent rare diseases or conditions affecting fewer than 200,000 people in the United States. The designation provides Sernova with the potential for seven years of market exclusivity in the United States upon regulatory approval, along with additional development incentives including tax credits for qualified clinical testing and waiver of certain FDA user fees, where applicable criteria are met.
Type 3c Diabetes (搜索): An Unmet Need
Type 3c diabetes (搜索), also known as pancreatogenic diabetes, occurs when damage to the pancreas impairs its ability to produce insulin and regulate blood glucose. This form of diabetes can result from conditions such as chronic pancreatitis (搜索), cystic fibrosis, pancreatic cancer, or other diseases affecting pancreatic function. Surgical removal of all or part of the pancreas, including total pancreatectomy performed to treat serious pancreatic conditions, results in type 3c diabetes due to the loss of insulin-producing pancreatic tissue. Patients with T3cD are treated in the same manner as those with type 1 diabetes (搜索) and face the same long-term co-morbidities.
Strategic Expansion
"Receiving Orphan Drug Designation from the FDA is an important milestone for Sernova," said Jonathan Rigby, Chief Executive Officer of Sernova. "Our primary focus remains advancing a functional cure for type 1 diabetes (搜索). At the same time, this designation provides Sernova a potential exclusive lead position in preventing type 3c diabetes (搜索). T3cD is a natural extension of our primary focus on T1D and we are planning to advance both of these programs in the coming months."
Sernova is preparing to initiate a clinical trial for autologous islet transplantation, with the goal of preserving insulin production and preventing post-surgical diabetes and its associated complex management and co-morbidities. The company's broader platform combines its Cell Pouch with human donor cells or stem-cell derived islet-like clusters, developed in collaboration with Evotec, to create bio-hybrid organs. A Bio-hybrid Organ comprises non-biomaterials, such as the Cell Pouch, integrated with living tissues and blood vessels to provide oxygen and nutrients to contained cells, aiming to restore or enhance the function of a compromised or explanted organ.
The company noted that orphan drug designation does not constitute FDA approval and does not guarantee that the product candidate will receive marketing approval or orphan drug exclusivity.